Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ACE | P12821 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1858577 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2ACEMAPTTAAR1THRB | |
| SCHEMBL9773201 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2ACEMAPTTAAR1THRB | |
| SCHEMBL10957115 | 0.90 | KMT2A (0.39) | SMN1; SMN2ACEMAPTHTTHSD17B10 | |
| SCHEMBL7722450 | 0.89 | SMN1; SMN2 (0.48) | SMN1; SMN2ACEMAPTMMP8PPARG | |
| SCHEMBL20676404 | 0.89 | ACE (0.37) | SMN1; SMN2ACEMAPTHTTHSD17B10 | |
| SCHEMBL7375987 | 0.88 | BLM (0.41) | BLMPPARGPPARAL3MBTL1 | |
| SCHEMBL5012826 | 0.88 | BLM (0.41) | BLMPPARGPPARAL3MBTL1 | |
| SCHEMBL8142297 | 0.88 | MEN1 (0.43) | SMN1; SMN2BLMPPARGPPARA | |
| SCHEMBL7344531 | 0.88 | BLM (0.41) | BLMPPARGPPARAL3MBTL1 | |
| SCHEMBL7728941 | 0.88 | MEN1 (0.43) | SMN1; SMN2BLMPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005122682-A2 | PROCESS FOR THE PREPARATION OF ESTERS OF PIPERAZIC ACID | RANBAXY LABORATORIES LIMITED (IN) | 2005-12-29 | — | — | WO | claimed |
| EP-3543225-B1 | METHOD FOR PREPARING LISINOPRIL INTERMEDIATE | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2023-01-04 | — | — | EP | disclosed |
| CN-109438449-B | Synthesis method of cilazapril containing hexahydropyridazine acid structure | 厦门医学院 | 2020-08-11 | — | — | CN | disclosed |
| US-20200231554-A1 | LIPOPHILIC MACROCYCLIC LIGANDS, COMPLEXES THEREOF, AND USES OF SAME | GUERBET (FR) | 2020-07-23 | — | — | US | disclosed |
| WO-2019016377-A1 | LIPOPHILIC MACROCYCLIC LIGANDS, COMPLEXES THEREOF, AND USES OF SAME | GUERBET (FR) | 2019-01-24 | — | — | WO | disclosed |
| EP-1383741-A4 | PROCESS FOR THE PREPARATION OF BENAZEPRIL | RANBAXY LAB LTD (IN) | 2006-01-04 | — | — | EP | disclosed |
| WO-2005122682-A2 | PROCESS FOR THE PREPARATION OF ESTERS OF PIPERAZIC ACID | RANBAXY LABORATORIES LIMITED (IN) | 2005-12-29 | — | — | WO | disclosed |
| US-6919450-B2 | Process for the preparation of benazepril | RANBAXY LABORATORIES LIMITED (IN) | 2005-07-19 | — | — | US | disclosed |
| WO-2005010028-A1 | ALPHA-AMINO ACID BENZOTHIAZOLYLTHIO ESTER AS INTERMEDIATES FOR MANUFACTURE OF ACE INHIBITORS AND PROCESS FOR PREPARATION THEREOF | LUPIN LIMITED (IN) | 2005-02-03 | — | — | WO | disclosed |
| US-20040152889-A1 | Process for the preparation of benazepril | RANBAXY LABORATORIES LIMITED (IN) | 2004-08-05 | — | — | US | disclosed |
| US-4999370-A | ANXIOLYTIC AGENTS, INHIBITORS OF ANGIOTENSIN CONVERTING ENZYME, NOOTROPIC AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-03-12 | — | — | US | disclosed |
| EP-0161801-B1 | PERHYDROTHIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANKYO COMPANY LIMITED (JP) | 1990-11-07 | — | — | EP | disclosed |
| US-4808713-A | Anthypertensive pyridazo [1,2-a][1,2]diazepines | HOFFMAN-LA ROCHE INC. (US) | 1989-02-28 | — | — | US | disclosed |
| US-4772701-A | Pyridazo[1,2]pyridazines and pyrazolo[1,2]pyridazines as antihypertensives | HOFFMANN-LA ROCHE INC. (US) | 1988-09-20 | — | — | US | disclosed |
| US-4734410-A | Lactam derivatives and their use as hypotensive agents | SANKYO COMPANY LIMITED (JP) | 1988-03-29 | — | — | US | disclosed |
| US-4699905-A | HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 1987-10-13 | — | — | US | disclosed |
| US-4658024-A | Pyrazolo [1,2-a][1,2]-diazepines useful as antihypertensives | HOFFMANN-LA ROCHE INC. (US) | 1987-04-14 | — | — | US | disclosed |
| EP-0161801-A2 | Perhydrothiazepine derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1985-11-21 | — | — | EP | disclosed |
| US-4525301-A | REACTING TRIFLUOROMETHANE SULFONIC ACID DERIVATIVES WITH AMINO ACID ESTERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-06-25 | — | — | US | disclosed |
| US-4512924-A | HYPOTENSIVE AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1985-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152889-A1 | Process for the preparation of benazepril | ACE, ACE2, REN | SMN1; SMN2 3400/4885ACE 1/4885MAPT 1533/4885 |
| US-20200231554-A1 | LIPOPHILIC MACROCYCLIC LIGANDS, COMPLEXES THEREOF, AND USES OF SAME | LDLR, NPC1L1, LRP6 | SMN1; SMN2 4820/4885ACE 2969/4885MAPT 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.